The researchers found that patients taking GLP-1 RAs had a significantly reduced incidence of revision FESS versus the non-GLP-1 RA group at one-year (risk ratio [RR], 0.64) and five-year follow-up ...
The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...
On Saturday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AMGN) announced full results from the Phase 3, registrational WAYPOINT trial evaluating the efficacy and safety of tezepelumab in ...
Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results